Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation.
Receptor tyrosine kinases (RTKs), in response to their growth factor ligands, phosphorylate and activate downstream signals important for physiological development and pathological transformation. Increased expression, activating mutations and rearrangement fusions of RTKs lead to cancer, inflammati...
Guardado en:
Autores principales: | Ramesh Narayanan, Muralimohan Yepuru, Christopher C Coss, Zhongzhi Wu, Matthew N Bauler, Christina M Barrett, Michael L Mohler, Yun Wang, Juhyun Kim, Linda M Snyder, Yali He, Nelson Levy, Duane D Miller, James T Dalton |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/99a4bb75c3cc4be7b28f17e6807eb989 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Photosensitive tyrosine analogues unravel site-dependent phosphorylation in TrkA initiated MAPK/ERK signaling
por: Shu Zhao, et al.
Publicado: (2020) -
Combinatorial assembly of small molecules into bivalent antagonists of TrkC or TrkA receptors.
por: Fouad Brahimi, et al.
Publicado: (2014) -
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
por: Ryohei Katayama, et al.
Publicado: (2019) -
Discovery and enantiocontrol of axially chiral urazoles via organocatalytic tyrosine click reaction
por: Ji-Wei Zhang, et al.
Publicado: (2016) -
Essential role for paxillin tyrosine phosphorylation in LPS-induced mitochondrial fission, ROS generation and lung endothelial barrier loss
por: Panfeng Fu, et al.
Publicado: (2021)